  Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  Signature [CONTACT_590491]-IQ Technology for High Insulin Users  with Type 1 
Diabetes (Higher-IQ) 
Protocol Identifying Number: TP-0009856  
IDE Number: G210300  
IDE Sponsor: Tandem Diabetes Care , Inc. 
Version Number : v 5.0 
21 MAR  2022  Medical Monitor and Protocol Chair  Name, degree  
Title  Jordan Pi[INVESTIGATOR_3388], MD  
Vice President & Medical Director, Tandem Diabetes Care  Signature/Date  Sponsor  Representative  Name, degree  
Title  Ravid Sasson -Katcha lski, PhD  
Associate Director, Clinical Affairs, Tandem Diabet es Care  Signature/Date  
B-1
 
   Confidential     
Contains trade secrets and/or confidential information exempt from disclosure from [ADDRESS_778122] Version Approved by [CONTACT_8415]  3.0 18 JAN 2022  • Added IDE number to cover page  
• Added protocol revision history table  
• Clarified  Stats Analysis Plan  endpoints , with detailed 
description of time periods for meal and exercise 
challenge analysis  
• Clarified  sponsor responsibilities  in AE/device issue 
reporting  
• Clarified exercise/meal challenge instructions  
• Removed S[LOCATION_003]R and other definitions not related to 
this trial , as investigational insulin will not be used  
• Clarified the sponsor’s Medical Director will serve as 
the Medical Monitor  
• Other minor clarifications on wording for consistency 
throughout the protocol  4.0 01 MA R 2022  • Clarified participant will plan to use  at leas t one  basal 
rate > 3 units/hr with the study pump.  
• Clarified participant s using SGLT -[ADDRESS_778123] 3 months prior to enrollment . 
• Clarified a bnormal screening electrocardiogram 
consistent with increased risk during study exercise 
activit ies, and that investigator will review all 
electrocardiograms.  
• Clarified procedures for verifying subject identifiers.  
• Added to section 7.1 that Humalog or Novolog will 
be provided  to participants . 
• Clarified details of monitoring plan , and specific data 
that would be considered source material that could be 
monitored.  
• Other minor clarifications on wording for consistency 
throughout the protocol . 5.0 21 MAR 2022  • Added Special Considerations for Participants Taking 
SGLT -2 inhibitors, GLP -1 Receptor Agonists, or DPP -
IV Inhibitors  to add scheduled ketone checks for 
participants using SGLT -2 inhibitors, when to stop B-2
 
   Confidential     
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  SGLT -2 inhibitors, and up dated hyperglycemia 
treatment guidelines.  
• Updated exclusion criteria to address adjuv ant 
medication use of glucose lowering agents and weight 
loss agents.  
• Updated prohibited medications.  
• Updated section 6.6.1 discontinuation of study 
device.  
• Updated inclusion criteria to note goal enrollment of 
at least 25% of participants using a basal rate above 3 
units/hr for substantially all day  
• Added definition of euglycemic DKA.    
B-3
 
   Confidential     
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  TABLE OF CONTENTS  
SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_66674]  ................................ ..............................  9 
CHAPTER 1: BACKGROUND INFORMATION  ................................ ................................ .............................  15 
1.1 Introduction  ................................ ................................ ................................ ................................ ....... 15 
1.1.1 Disease Background  ................................ ................................ ................................ ....................  15 
1.1.2 Tandem X2 Insulin Pump with Control -IQ Technology  ................................ .............................  15 
1.2 Rationale  ................................ ................................ ................................ ................................ ............  15 
1.3 Potential Risks and Benefits  ................................ ................................ ................................ ..............  15 
1.3.1 Known Potential Risks  ................................ ................................ ................................ ................  15 
[IP_ADDRESS] Blood Draw  ................................ ................................ ................................ .........................  15 
[IP_ADDRESS] CGM and Pump Catheter Risks  ................................ ................................ ..........................  16 
[IP_ADDRESS] Hypoglycemia  ................................ ................................ ................................ .....................  16 
[IP_ADDRESS] Risk of Hyperglycemia  ................................ ................................ ................................ ....... 16 
[IP_ADDRESS] Risk of Device Reuse  ................................ ................................ ................................ ..........  16 
[IP_ADDRESS] Potential Risks of the CLC System  ................................ ................................ .....................  16 
[IP_ADDRESS] Other Risks  ................................ ................................ ................................ ..........................  17 
1.3.2 Benefits  ................................ ................................ ................................ ................................ ........  17 
1.3.3 Risk Assessm ent ................................ ................................ ................................ ..........................  17 
1.4 General Considerations  ................................ ................................ ................................ ......................  17 
CHAPTER 2: STUDY ENROLLMENT AND LEAD-IN PERIOD  ................................ ................................ ...... 18 
2.1 Participant Recruitment and Enrollment  ................................ ................................ ...........................  18 
2.1.1 Informed Consent and Authorization Procedures  ................................ ................................ ....... 18 
2.2 Participant Eligibility Criteria  ................................ ................................ ................................ ...........  18 
2.2.1 Inclusion Criteria  ................................ ................................ ................................ .........................  18 
2.2.2 Exclusion Criteria  ................................ ................................ ................................ ........................  19 
2.3 Screening Procedures  ................................ ................................ ................................ ........................  20 
2.3.1 Data Collection and Testing  ................................ ................................ ................................ ........  20 
2.4 Screen Failures  ................................ ................................ ................................ ................................ .. 21 
CHAPTER 3: TREATMENT PERIOD ................................ ................................ ................................ ............  22 
3.1 Control -IQ 1.5 Training Visit  ................................ ................................ ................................ ............  22 
3.1.1 Training on System Use  ................................ ................................ ................................ ..............  22 
3.1.2 Training on Management of Hypoglycemia  ................................ ................................ ................  23 
3.1.3 Training on Management of Hyperglycemia  ................................ ................................ ...............  23 
3.1.4 Adjustments in Insulin Pump Settings  ................................ ................................ ........................  24 B-4
 
   Confidential     
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  3.2 Study Visits and Phone Contacts  ................................ ................................ ................................ ....... 25 
3.2.1 Procedures at Study Visits  ................................ ................................ ................................ ...........  25 
3.2.2 Unscheduled Visits  ................................ ................................ ................................ ......................  26 
3.2.3 Exercise and Meal Challenges  ................................ ................................ ................................ ..... 26 
3.3 Early Discontinuation of Study Device  ................................ ................................ .............................  26 
CHAPTER 4: STUDY DEVICES AND DRUGS  ................................ ................................ ...............................  27 
4.1 Study Devices  ................................ ................................ ................................ ................................ .... 27 
4.1.1 Insulin Pu mp ................................ ................................ ................................ ................................  27 
4.1.2 Continuous Glucose Monitoring  ................................ ................................ ................................ . 27 
4.1.3 Blood Glucose Meter  ................................ ................................ ................................ ...................  27 
4.1.4 Ketone Meter  ................................ ................................ ................................ ...............................  27 
4.2 Study Devi ce and Drug Accountability Procedures  ................................ ................................ ..........  27 
4.3 Participant Access to Study Device at Study Closure  ................................ ................................ ....... 27 
CHAPTER 5: TESTING PROCEDURES AND QUESTIONNAIRES ................................ ................................ .. 28 
5.1 Meal and Exercise Challenges  ................................ ................................ ................................ ...........  28 
5.1.1 Meal Challenges  ................................ ................................ ................................ ..........................  28 
5.1.2 Exercise Challenges ................................ ................................ ................................ .....................  29 
5.2 Laboratory Testing  ................................ ................................ ................................ ............................  29 
5.2.1 HbA1c  ................................ ................................ ................................ ................................ .........  29 
5.2.2 Urine Pregnancy  ................................ ................................ ................................ ..........................  29 
CHAPTER 6: UNANTICIPATED PROBLEM , ADVERSE EVENT , AND DEVICE ISSUE REPORTING  ............  30 
6.1 Unanticipated Problems  ................................ ................................ ................................ .....................  30 
6.2 Adverse Events  ................................ ................................ ................................ ................................ .. 30 
6.2.1 Definitions  ................................ ................................ ................................ ................................ ... 30 
6.2.2 Reportable  Adverse Events  ................................ ................................ ................................ .........  31 
6.2.3 Hypoglycemic Events  ................................ ................................ ................................ ..................  32 
6.2.4 Hyperglycemic/Ketotic Events  ................................ ................................ ................................ .... 32 
6.2.5 Relationship of Adverse Event to Study Investigational Device  ................................ .................  33 
6.2.6 Severity (Intensity) of Adverse Events  ................................ ................................ ........................  33 
6.2.7 Expectedness  ................................ ................................ ................................ ...............................  34 
6.2.8 Coding of Adverse Events  ................................ ................................ ................................ ...........  34 
6.2.9 Outcome of Adverse Events  ................................ ................................ ................................ ........  34 
6.3 Reportable Device Issues  ................................ ................................ ................................ ...................  34 
6.4 Timing of Event Reporting  ................................ ................................ ................................ ................  35 
6.5 Safety Oversight  ................................ ................................ ................................ ................................  35 B-5
 
   Confidential     
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  6.6 Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ ...............................  36 
6.6.1 Participant Discontinuation of Study Device  ................................ ................................ ..............  36 
6.6.2 Criteria for Suspending or Stoppi[INVESTIGATOR_3396]  ................................ ................................ ..... 36 
CHAPTER 7: MISCELLANEOUS CONSIDERATIONS  ................................ ................................ ...................  38 
7.1 Drugs Used as Part of the Protocol  ................................ ................................ ................................ .... 38 
7.2 Collection of Medical Conditions and Medications  ................................ ................................ ..........  38 
7.3 Prohibited Medications, Devices, Treatments, and Procedures  ................................ .........................  38 
7.4 Rescue Medications, Treatments, and Procedures  ................................ ................................ ............  38 
7.5 Pregnancy Reporting  ................................ ................................ ................................ .........................  38 
7.6 Participant Compensation  ................................ ................................ ................................ ..................  39 
7.7 Participant Withdrawal  ................................ ................................ ................................ ......................  39 
CHAPTER 8: STATISTICAL CONSIDERATIONS  ................................ ................................ ..........................  40 
8.1 Statistical Hypotheses  ................................ ................................ ................................ ........................  40 
8.2 Sample Size  ................................ ................................ ................................ ................................ ....... 40 
8.3 Outcome Measures  ................................ ................................ ................................ ............................  40 
8.4 Analysis Datasets  ................................ ................................ ................................ ...............................  40 
8.5 Statistical Methods  ................................ ................................ ................................ ............................  41 
8.5.1 Anal ysis of the Safety Event Endpoints  ................................ ................................ ......................  41 
8.5.2 Analysis of CGM Endpoints  ................................ ................................ ................................ ....... 41 
8.5.3 Intervention Adherence  ................................ ................................ ................................ ...............  41 
8.6 Protocol Adherence and Retention  ................................ ................................ ................................ .... 41 
8.7 Baseline Descriptive Statistics  ................................ ................................ ................................ ...........  41 
8.8 Additional Tabulations and Analyses  ................................ ................................ ................................  42 
8.9 Device Issues  ................................ ................................ ................................ ................................ ..... 42 
8.10 Planned Interim Analyses  ................................ ................................ ................................ ................  42 
8.11 Subgroup Analyses  ................................ ................................ ................................ ..........................  42 
8.12 Multiple Comparison/Multiplicity  ................................ ................................ ................................ ... 42 
8.13 Analysis of Meal and Exercise Challenges  ................................ ................................ .....................  42 
CHAPTER 9: DATA COLLECTION AND MONITORING  ................................ ................................ ..............  43 
9.1 Case Report Forms and Other Data Collection  ................................ ................................ .................  43 
9.2 Study Records Retention  ................................ ................................ ................................ ...................  43 
9.3 Qu ality Assurance and Monitoring  ................................ ................................ ................................ .... 43 
9.4 Protocol Deviations  ................................ ................................ ................................ ...........................  44 
CHAPTER 10: ETHICS /PROTECTION OF HUMAN PARTICIPANTS  ................................ ............................  [ADDRESS_778124]  ................................ ................................ ................................ ...............................  45 B-6
 
   Confidential     
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  10.2 Institu tional Review Boards  ................................ ................................ ................................ ............  45 
10.3 Informed Consent Process  ................................ ................................ ................................ ...............  45 
10.3.1 Consent Procedures and Documentation  ................................ ................................ ...................  45 
10.3.2 Participant and Data Confidentiality  ................................ ................................ .........................  45 
10.3.3 Future Use of Stored Specimens and Data  ................................ ................................ ................  46 
CHAPTER 11: REFERENCES  ................................ ................................ ................................ .......................  47 
 
 
 
B-7
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from [ADDRESS_778125]  Diabetes Control  & Complications Trial  DKA  Diabetic Ketoacidosis  eCRF  Electronic Case Report Form  FDA  Food and Drug Administration  GCP  Good Clinical Practice  HbA1c  Hemoglobin A1c  ICF Informed consent form  ICH  International Conference of Harmonisation  IDE  Investigational Device Ex emption  IRB Institutional Review Board  RBM  Risk-Based Monitoring  SAE  Serious Adverse Event  T1D  Type [ADDRESS_778126]   
B-8
 
  Confident ial 
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  
 Site Principal Investigator [INVESTIGATOR_590478]:  TP-0009856  Protocol Name:  [CONTACT_66727] -IQ Technology for High Insulin Users with 
Type 1 Diabetes (Higher -IQ) Protoco l Version  / Date : 5.0 / 21 MAR  2022   
The Principal Investigators (undersigned) hereby [CONTACT_590483].  
This trial will be carried out in accordance with the principles of Good Clinical Practice (GCP) 
and as required by [CONTACT_716] , as applicable: [LOCATION_002] (US) Code of Federal Regulations 
(CFR) (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 
812).  
By [CONTACT_66692], the investigators ag ree to the above and to fully co -operate 
with all monitoring and audits in relation to this trial by [CONTACT_274958], including source data, by [CONTACT_590484], Inc., IRBs and/or by [CONTACT_941] U S Federal, State and local regulatory authorities.  
 
Investigator Name:  ________________________________________ ___ 
 
Investigator Signature:  ________________________________________  
 
Date (DD/MMM/YYYY):  ______________________________________  
 
B-9
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  PROTOCOL SUMMARY  Study Sponsor  Tandem Diabetes Care, Inc.  Protocol Number  TP-0009856  Protocol Title  Control -IQ Technology for High Insulin Users with Type 1 Diabetes (Higher -IQ) Précis A prospective, single -arm study of 13 weeks of home use of the Control -IQ automated 
insulin delivery (AID) system  in individuals with type [ADDRESS_778127] one basal rate > 3 units/hr, age 18 and older . Subjects will use the Control -IQ 1.5 
System . Exercise and meal challenges will be performed during the study.  Products  t:slim X2 insulin pump with Control -IQ technology v1.5 (Control -IQ System)  Objectives  The objective s of the study are to assess  safety  and explore glycemic outcomes with use of  
an automated insulin delivery  (AID) system (t:slim X2 with Control -IQ Technology  v1.5) in 
adults with type [ADDRESS_778128] one  basal rate > 3 units/hr.  Number of Sites  Up to 5  clinical sites  in the US.  Study Design  Existing insulin pump users (to include AID users) will use the study system (pump and 
CGM) in closed -loop mode for [ADDRESS_778129] 30 finish closed -loop use.                                                                                                                                                                               Participant Population:  Eligibility to enroll in the study will be assessed based on the following inclusion 
criteria:  
1. Age ≥ [ADDRESS_778130] 1 year  
3. Currently using an insulin pump (of any brand) for at least [ADDRESS_778131] one basal rate above 3 units/hr  with the study pump  
a. Goal is at least 25% of study participants are on a basal rate above 3 
units/hr for substantially all day  
4. HbA1c < 10.5%  
5. Weight ≤ 200 kg  
6. Residing full -time in the [LOCATION_002], with no anticipated travel outside the 
[LOCATION_002] during the period of study participation.  
7. Participant has agreed to participate in the study; and has read, understood and 
signed the informed consent form (ICF) ; and has agreed to follow all study 
procedures, including suspending use of any personal CGM for the duration of the 
clinical trial once the study CGM is in use.  
8. Willing to use only aspart (novolog) or lispro (humalog) insulin with the study 
pump, with no  use of concentrated insulin above U -100, long -acting basal insulin 
injections, or inhaled insulin  with the study pump  
9. Have current glucagon product to treat severe hypoglycemia (injectable or nasal) 
at home (will provide prescription if they do not have o ne) 
10. Willing and able to perform the study exercise and meal challenges.  
11. Have a care partner, t rained in hypoglycemia and hyperglycemia treatment 
guidelines, present during the challenges and until the next day.  
12. Investigator has confidence that the partici pant can successfully operate all study 
devices and is capable of adhering to the protocol, including ability to respond to 
alerts and alarms, and to provide basic diabetes self -management.  
Eligibility to enroll in the study will be assessed based on the f ollowing exclusion 
criteria:   
1. More than 1 epi[INVESTIGATOR_44715] d iabetic ketoacidosis (DKA) in the past 6 months  
2. More than 1 epi[INVESTIGATOR_66677] (needing assistance) in the past 6 
months  B-10
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from [ADDRESS_778132] 6 months  
4. History of drug abuse (defined as any illicit drug use) or history of alcohol abuse 
prior to screening or unwillingness to agree to abstain from illicit drugs throughout 
the study.  
5. For Female: Currentl y pregnant or planning to become pregnant during the time 
period of study participation  
• A negative pregnancy test will be required for all females of child -
bearing potential  
• Counseling on appropriate birth control options will be provided to all 
females of child -bearing potential  
6. Use of sulfonylureas, meglitinides, Symlin or other medications specifically listed 
in section 7.[ADDRESS_778133] udy 
12. Abnormal screening electrocardiogram consistent with increased risk  during study 
exercise  activit ies, such as arrhythmia, ischemia, or prolonged QTc interval . 
Investigator will review all electrocardiogram s 
13. Significant chronic kidney disease (which could impact CGM accuracy in 
investigator’s judgment) or hemodialysis  
14. History of adrenal insufficiency  
15. History of abnormal TSH consistent with hypothyroidism or hyperthyroidism that 
is not appropriately treated  
16. History of gastroparesis  
17. A condition, which in the opi[INVESTIGATOR_66678], would put the 
participant or study at risk  
18. Participation in another pharmaceutical or device trial at the time of enrollment or 
anticipated for during the time period of study participation  
19. Employed by,  or having immediate family members employed by [CONTACT_590485], Inc., or having a direct supervisor at place of employment who is 
also directly involved in conducting the clinical trial (as a study investigator, 
coordinator, etc.); or having a first -degree relative  who is directly involved in 
conducting the clinical trial                                                       
Participant Duration  Approximately 13-15 weeks . 
B-11
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  Study Endpoints  Primary Safety Endpoints:  
• Severe hypoglycemia ( with cognitive impairment such that assistance  of another 
individual is needed for treatment ) during study compared with data on severe 
hypoglycemic events reported by T1D Exchange clinic registry over a 3 -month time 
period  
• Diabetic ketoacidosis  (event rate) 
• Number of unanticipated adverse device effects  
• Number of other s erious adverse events  
Secondary Safety Endpoints:  
• All adverse events  
• CGM hypoglycemia outcomes  
◆ Overall % time <54 mg/dL  
◆ Overall % time <70 mg/dL  
Exploratory:  
• Times in ranges -overall  (70-180 mg/dL, >180 mg/dL, >250 mg/dL , 70-140 mg/dL ) 
• Mean glucose  
• Overall variability (CV and SD)  
• HbA1c change  from baseline   
• CGM metrics for hypoglycemia, hyperglycemia, and variability during daytime and 
nighttime  Protocol Overview/Synopsis  After consent is signed, eligibility will be assessed.  
 
Treatment  Period : 
Participants will return to clinic to undergo device training with the study CGM and study 
pump.  
Participants will then use the study pump for ~[ADDRESS_778134] a phone follow up visit at 3 days, 1 week, 3 weeks, a n in clinic visit at 6 weeks, a 
phone follow up visit at 9 weeks, and a final clinic visit at  ~13 weeks.  
Participants will use the t:slim X2 insulin pump with Control -IQ technology 1.5 turned on. It 
is acceptable to use manual mode when there is a loss of CGM data.  
Each participant will perform 3 meal and 3 exercise challenges during the study.  
An assessment of adverse events, using open ended questions to capture hyperglycemic and 
hypoglycemic events, and their underlying cause and relationship to the study device or 
other parts of the system (such as the infusion set), will occur at all visits/contacts.  
Study Safety Plan :  
Participants will be given a bloo d glucose and ketone meter to use throughout the study,  and 
will be trained on their use by [CONTACT_3436]. BGM readings will be performed  
in accordance with the study participant instruction sheet  and per CGM manufacturer 
instructions. Ketone  readings will be performed per the study participant instruction sheet . 
Site investigators may adjust insulin delivery profile settings as needed throughout the study 
in accordance with their clinical practice .  
B-12
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  SCHEMATIC OF STUDY DESIGN 
 
B-13
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from [ADDRESS_778135] from the study. Note, HbA1c (Central Lab) 
will only be drawn if the subject  has reached at least [ADDRESS_778136] does not need to be repeated if screening and Control -IQ training visits are performed on 
the same day. Screening 
Visit  Control -IQ 
1.5 Training 
Visit   Control -IQ Use    Up to 2 
weeks  after 
screening  3d 1w 3w 6w 9w 13w1 UV Visit (V) or Contact (C)  V V C C C V C V V/C Informed Consen t X         Eligibility Assessment  X         Medical history/  
physical exam  X         Height, weight, 
blood  pressure  and pulse  X         HbAlc (POC or local lab ) X         ECG X         Pregnancy test  (females 
of child -bearing potential) X X2        Assessment of Device  Use X         Study system training   X        HbA1c (Central Lab)   X      X  AE Assessment   X X X X X X X X Upload and Review Study 
Device Data    X X X X X X X 
B-14
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  Chapter 1:  Background Information  1 
1.1 Introduction  2 
1.1.1  Disease Background  3 
Type 1 diabetes affe cts 1.25 million people in the [LOCATION_002]. Approximately 70% of individuals with 4 
type 1 diabetes report poor metabolic control, and do not meet the American Diabetes Association’s 5 
recommended goal of hemoglobin A1c  (HbA1c) level of 7.0% . These findings indicate the need for better 6 
approaches to type 1 diabetes management.  7 
1.1.2  Tandem X2 Insulin Pump with Control -IQ Technology  8 
The Tandem X2 insulin pump with Control -IQ technolo gy is an FDA -approved closed -loop control 9 
(CLC) system based on the control algorithm developed and initially tested in the University of 10 
Virginia’s  DiAs system and then implemented in the inControl system (TypeZero, Technologies, Inc.). 11 
Use of the Control -IQ system has been extensively tested in adults and children with type 1 diabetes 12 
(T1D), demonstrating its efficacy and safety when used with insulin lispro (Humalog) or insulin aspart 13 
(Novolog).1,2 The system is currently approved for ages 6 years and ol der and use in younger children is 14 
currently being studied (clinical trials.gov [STUDY_ID_REMOVED] ). There are over 150,000 users of the 15 
system  since it became commercially available in 2020 . A recent evaluation of real -world use of the 16 
system in 9,451 users age >[ADDRESS_778137] usability improvements and other enhancements 20 
intended to further reduce risk. The Control -IQ 1.5 system also removes the 3 units/hr basal clippi[INVESTIGATOR_007], 21 
allowing the pump  to deliver programmed user profile basal rates above 3 units/hr  when 30 minute 22 
predicted glucose is expected to be in the target range . This has the potential to further improve outcomes 23 
in individuals using basal rates at or above this threshold.  24 
1.2 Rationa le 25 
The objective of this single -arm, prospective study is to assess safety and explore glycemic outcomes 26 
associated with use of the Control -IQ 1.5 system  in adults with type  1 diabete s using basa l rates > 3 27 
units/hr for at least part of the day .  28 
1.3 Potential Risks and Benefits  29 
Risks and Benefits are detailed below. Loss of confidentiality is a potential risk; however, data are 30 
handled to minimize this risk . Hypoglycemia, hyperglycemia and ketone formation are always a risk in 31 
participants with type 1  diabetes and participants will be monitored for these events . 32 
1.3.1  Known Potential Risks  33 
[IP_ADDRESS]  Blood Draw  34 
A venipuncture and/or fingerstick will be performed to obtain blood for HbA1c measurement . [ADDRESS_778138] for 39 
several weeks . The risk of local infection is less than 1 in 1000 with either venipuncture or fingerstick.  40 B-15
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  [IP_ADDRESS]  CGM and Pump Catheter Risks  41 
There is a small risk of bleeding whe re the sensor or infusion set is inserted. There is a small risk for 42 
developi[INVESTIGATOR_007] a local skin infection at the site of CGM sensor placement of pump infusion set placement . 43 
This may be associated with swelling, redness and pain; and may require antibiotic th erapy . Rarely, a [ADDRESS_778139] a small portion of the sensor under the skin that may cause redness, 45 
swelling or pain at the insertion site.  46 
Some participants may develop skin irritation or allergic reactions to the adhesives used to secure  the 47 
CGM, or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion . If these 48 
reactions occur, different adhesives or “under -tapi[INVESTIGATOR_007]” (such as with IV 3000, Tegaderm, etc.) will be 49 
tried, sites will be rotated frequently, and a  mild topi[INVESTIGATOR_66679] 50 
required.   51 
[IP_ADDRESS]  Hypoglycemia  52 
As with any person having type 1 diabetes and using insulin, there is always a risk of having 53 
hypoglycemia . The frequency of hypoglycemia should be no more and possibly less tha n it would be 54 
as part of daily living . Symptoms of hypoglycemia can include sweating, jitteriness, and not feeling well . 55 
There is the possibility of fainting or seizures (convulsions) and that for a few days the participant may 56 
not be as aware of symptoms of hypoglycemia . A CGM functioning poorly and significantly over - 57 
reading  glucose values could lead to inappropriate insulin delivery.  58 
[IP_ADDRESS]  Risk of Hyperglycemia  59 
Hyperglycemia and ketonemia could occur if insulin delivery is attenuated or suspended for an 60 
extend ed period or if the pump or infusion set is not working properly . A CGM functioning poorly 61 
and significantly under -reading glucose values could lead to inappropriate suspension of insulin delivery.  62 
[IP_ADDRESS]  Risk of Device Reuse  63 
All devices will be used by a single study participant only. There will be no device reuse.  64 
[IP_ADDRESS]  Potential Risks of the CLC System  65 
Even though the study system has been tested prior to this study, there is still a risk that parts of the 66 
system may not function properly. The following are possible reasons the system may deliver too much 67 
insulin or incorrectly stop insulin delivery:  68 
• CGM sensor reads higher or lower than the actual glucose level which increases risk for 69 
hypoglycemia and hyperglycemia with automated insulin delivery system;  70 
• Device malf unctions that could produce a suspension of insulin delivery or over delivery of insulin.  71 
B-16
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  [IP_ADDRESS]  Other Risks  72 
Data downloaded from the study CGM  and study pump will be collected for the study. The downloaded 73 
data from the participant’s  home pump  and CGM (if available)  at the screening visit  will include data [ADDRESS_778140] 2 weeks 75 
prior to screening. Some people may  be uncomfortable with the researchers' having such detailed 76 
information about their daily diabetes habits.  77 
1.3.2  Benefits  78 
Participants may achieve better glucose control than they are currently achieving using the ir hom e insulin 79 
pump .  80 
The individual participant may not benefit from study participation.  81 
1.3.3  Risk Assessment  82 
Based on the facts that (1) individuals with diabetes experience mild hypoglycemia and hyperglycemia 83 
frequently as a consequence of the disease and its ma nagement,  (2),  mitigations are  in place, and have 84 
been tested in prior studies using the investigational device system in the home setting, that limit the 85 
likelihood of excessive insulin dosing or prolonged withdrawal of insulin, and ( 3) rapid reversal of  [ADDRESS_778141] their origin in the 92 
Declaration of Helsinki, with the protocol described  herein, and with the standards of Good Clinical 93 
Practice (GCP).   [ADDRESS_778142] that the intervention is investigational . Therefore, an investigational device exemption (IDE) from the 98 
U.S. Food and Drug Administration (FDA) is required to conduct the study.  99 
 100 
B-17
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  Chapter 2:  Study Enrollment and Lead -in Period  [ADDRESS_778143] the overall recruitment goal.                                                                                                                                                                                                                                                                                                                                             107 
2.1.1  Informed Consent  and Authorization Procedures  108 
Potential eligibility may be assessed as part of a routine -care examination . Before  completing any 109 
procedures or collecting any data that are not part of usual care, written  or electronic  informed consent 110 
will be obtained.  111 
For potential study participants, the study protocol will be discussed with the potential study participant 112 
by [CONTACT_464] . The potential study participant will be given the Informed Consent Form  to read . Potential 113 
study participants will be encouraged to discuss the study with family members and their personal 114 
physicians(s) before deciding whether to participate  in the study.  115 
A copy of the consent form will be provided to the participant , and a copy will be added to the 116 
participant’s study record.  [ADDRESS_778144] meet all of the following inclusion criteria in order to be eligible to partic ipate in the 125 
study.  126 
1. Age ≥ [ADDRESS_778145] 1 year  128 
3. Currently using an insulin pump (of any brand)  for at least [ADDRESS_778146] 129 
one basal rate above 3 units/hr  with the study pump  [ADDRESS_778147] 25%  of study participants are on a basal rate above 3 units/hr for 131 
substantially all day  132 
4. HbA1c < 10.5%  133 
5. Weight ≤ 200 kg  134 
6. Residing full -time in the [LOCATION_002], with no anticipated travel outside the [LOCATION_002] during 135 
the period of study participation.  136 
7. Participant has agreed to participate in the study; and has read, understood and signed the 137 
informed consent form (ICF); and has agreed to follow all study procedures, including  138 B-18
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  suspending use of any personal CGM for the duration of the clin ical trial once the study CGM is 139 
in use . 140 
8. Willing to use only aspart (novolog) or lispro (humalog) insulin with the study pump, with no use [ADDRESS_778148] to treat severe hypoglycemia (injectable or nasal) at home (will [ADDRESS_778149] one)  [ADDRESS_778150] a care partner, trained in hypoglycemia and hyperglycemia treatment guidelines, present 147 
during the challenges and until the next day.  148 
12. Investigator has confidence that the participant can successfully operate all study devices and is 149 
capable of adhering to the protocol, including ability to respond to alerts and alarms, and to 150 
provide basic diabetes self -management.  151 
2.2.2  Exclusion Criteria  152 
Individuals meeting any of the following exclusion criteria at baseline will be excluded from study 153 
participation.  154 
1. More than 1 epi[INVESTIGATOR_66676] (DKA) in  the past 6 months  155 
2. More than 1 epi[INVESTIGATOR_66677] (needing assistance) in the past [ADDRESS_778151] 6 months  157 
4. History of drug abuse (defined as any illicit drug use) or history of alcohol abuse prior to 158 
screen ing or unwillingness to agree to abstain from illicit drugs throughout the study.  159 
5. For Female: Currently pregnant or planning to become pregnant during the time period of study 160 
participation  161 
• A negative pregnancy test will be required for all females of child -bearing potential  162 
• Counseling on appropriate birth control options will be provided to all females of child - [ADDRESS_778152], or DPP -4 inhibitor as listed in 167 
section 7.3 of the protocol, or starting a new non-insulin glucose lowering or weight loss agent 168 
during the trial  169 
8. Hemophilia or any other bleeding disorder  170 
9. History of heart, liver, lung or kidney disease determined by [CONTACT_66701] 171 
study  172 
10. Histor y of allergic reaction to Humalog or Novolog  173 
11. Use of glucocorticoids or other medications determined by [CONTACT_66699]  174 
12. Abnormal screening electrocardiogram consistent with increased risk during study exercise  175 
activities , such as arrhyt hmia, ischemia, or prolonged QTc interval . Investigator will review all 176 
electrocardiograms  177 B-19
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  13. Significant chronic kidney disease (which could impact CGM accuracy in investigator’s 178 
judgment) or hemodialysis  [ADDRESS_778153] of employment w ho is also directly involved in conducting the 189 
clinical trial (as a study investigator, coordinator, etc.); or having a first -degree relative who is [ADDRESS_778154] physical exam (including vital signs and height and weight measurements) will be performed 197 
by [CONTACT_3437] (a physician, fellow, nurse practitioner or a physician assistant).  198 
Height, weight and v ital signs may be recorded by [CONTACT_66702].  199 
The following procedures will be performed/data collected/eligibility criteria checked and documented:  200 
• Inclusion and exclusion criteria assessed  201 
• Demographics ( age, sex, race and ethni city and socioeconomic information ) 202 
• Subject initials to verify downloaded device data and eCRF entry is associated with the correct 203 
individual  204 
• Contact [CONTACT_3031] (retained at the site and not entered into study database)  205 
• Medical history  206 
• Substance use his tory (drinking, smoking, and drug habits)  207 
• Concomitant medications  208 
• Physical examination to include:  209 
 Weight, height  210 
 Vital signs including measurement of blood pressure and pulse  211 
• Blood draw (venipuncture or fingerstick) for local HbA1c measurement  212 
• Urine pregnancy test for all females who are premenopausal and not surgically sterile  213 
• ECG performed at screening for all participants  214 B-20
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  • Current device download, to include insulin pump and CGM device data , for up to the last [ADDRESS_778155] occur in clinic and 217 
cannot be performed remotely.  218 
2.4 Screen Failures  219 
Individuals who do not initially meet study eligibility requirements may be rescreened one more time at a 220 
later date per investigato r discretion.  221 
 222 
B-21
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  Chapter 3:  Treatment Period  [ADDRESS_778156] occur in clinic an d cannot  be performed remotely.  231 
A blood sample (venipuncture or fingerstick) will be obtained to send to the central laboratory for [ADDRESS_778157] for all females who are premenopausal and not surgically sterile will be 234 
completed . 235 
Participants will receive supplies for blood glucose and ketone testing. Quality Control ( QC) testing will 236 
be performed on the meters before they are dispensed.  237 
As all study participants are existing pump users  (of any brand pump) , pump settings will be transferred 238 
over from the participant ’s current pump. The study investigator may then f urther adjust insulin delivery 239 
profile settings as clinically indicated.   240 
3.1.1  Training on System Use  241 
All participants will receive study system training from a qualified trainer.  242 
At a minimum training will include the following:  243 
• Calibration of the CGM in accordance with manufacturer labeling  244 
• Procedures for treating severe hypoglycemia  245 
• Procedures for iden tifying potential infusion set failure and steps to take including the checking of the [ADDRESS_778158] or office visit.  250 
The participant will be instructed to use the system in closed -loop mode except 1) when no calibr ated 251 
CGM sensor is available or 2) if insulin is delivered by [CONTACT_3451] (e.g. 252 
injection of subcutaneous insulin via syringe in the event of infusion site failure). If insulin is delivered [ADDRESS_778159] study staff during periods of illness with an elevated 256 
temperature >101.5 degrees Fahrenheit (38.6 degrees Celsius), period s of significant illness, or during 257 
periods of use of medications such as epi[INVESTIGATOR_27979] a severe allergic 258 
reaction or asthma attack in addition to use of oral or injectable glucocorticoids to determine if closed - 259 
loop use should  be temporarily discontinued.  260 
Participants taking SGLT -2 inhibitors will be instructed to discontinue use of their SGLT -2 inhibitor 261 
during times of illness  where they are at higher risk to develop ketones, to include temperature  >101.5 262 B-22
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  degrees Fahrenheit ( 38.6 degrees Celsius), any gastrointestinal illness, dehydration, decreased PO intake, [ADDRESS_778160] -party 270 
components for this purpose. The t:connect mobile app from Tandem Diabetes Care will not be [ADDRESS_778161] is required as per the study visit schedule 273 
and will make arrangements with the participant for the contacts . If the participant cannot be reached, the 274 
participant’s other contact [CONTACT_367230], including the emergency contact . Participants who are [ADDRESS_778162] a care partner , trained in the study hypoglycemia  and 278 
hyperglycemia treatment guidelines,  present during the study  meal and exercise challenges, and present 279 
overnight after the challenges. These hypoglycemia an d hyperglycemia treatment guidelines will be 280 
reviewed with the care partner prior to initiating any challenges.  281 
Following the Control -IQ 1.5 Training Visit, participants will use the study pump for ~90 days during the 282 
Treatment Period.  283 
3.1.2  Training on Management of Hypoglycemia  284 
The t:slim X2 with Control -IQ system will issue a predictive hypoglycemia alert (Control -IQ Low Alert) 285 
when the system predicts BG <70 mg/dL within the next 15 minutes (<80 mg/dL when exercise mode is 286 
activated). Participants wil l be permitted to change the CGM low glucose threshold alert setting on their 287 
device or mobile app, but will be instructed to choose a value no less than 70 mg/dL.  288 
If the participant receives a Control -IQ Low Alert, a message appears on the user interface that is 289 
accompanied by [CONTACT_66703]/or sound if not acknowledged by [CONTACT_30799] [ADDRESS_778163] lower blood glucose levels after meals.  294 
The participant and companion if available will be instructed that if severe hypoglycemia occurs, the 295 
study pump’s insulin delivery should be suspended and glucagon administration if the participant is [ADDRESS_778164] one will be given a prescription for the glucagon emergency kit.  299 
3.1.3  Training on Management of Hyperglycemia  300 
The t:slim X2 with Control -IQ system will issue a predictive hyperglycemia alert (Control -IQ High Alert) 301 
when the system has increased insulin delivery, but detects a CGM value above 200 mg/dL and does not [ADDRESS_778165] the value will decrease in the next 30 minutes. During the course of the study, participants will be 303 
permitted to change the CGM high glucose threshol d alert setting on their device or mobile app, but will 304 
be instructed to choose a value no greater than 300 mg/dL.  305 B-23
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from [ADDRESS_778166] blood gl ucose.  307 
If a participant’s CGM reading is >300 mg/dL for more than 60 minutes or is ≥400 mg/dL at any point, 308 
the participant will be instructed to take the following steps:  309 
• Perform a blood glucose meter check.  310 
• If the blood glucose is >300 mg/dL, check for b lood ketones with the study ketone meter.  311 
• If the ketone level is ≥ 0.6 mmol/L (or ≥ 2.5 mmol \L at any time), take correction insulin, change 312 
insulin (pump) infusion site and contact [CONTACT_464] . Continue to monitor their glucose and blood 313 
ketone levels unt il they return to normoglycemia and ketones are < 0.6 mmol/l.  314 
 If ketones are <0.6 mmol/l, they will be advised to continue to monitor their glucose until it 315 
returns to normoglycemia and to repeat the ketone measurement in 90 minutes if necessary  316 
• If correct ion insulin is administered via insulin syringe, turn Control -IQ off for four hours and until 317 
glucose level has returned to <180 mg/dL.  [ADDRESS_778167] 323 
twice a day (morning and evening) during the first two weeks of study device use , and at least once a day 324 
thereafter . If a participant takin g an SGLT -2 inhibitor develop ketones > 0.6 on two successive occasions 325 
during these 2 weeks (the first testing upon waking in a fasted state), they will be withdrawn from the [ADDRESS_778168], or DPP -4 inhibitor, i f a 329 
participant’s CGM reading is > 250 mg/dL for more than 60 minutes or is ≥400 mg/dL at any point, the 330 
participant will be instructed to take the following steps:  331 
• Perform a blood glucose meter check.  332 
• If the blood glucose is > 250 mg/dL, check for blood ketones with the study ketone meter.  333 
• If the ketone level is ≥ 0.6 mmol/L (or ≥ 2.5 mmol \L at any time), take correction insulin, change 334 
insulin (pump) infusion site and contact [CONTACT_464]. Continue to monitor their glucose and b lood 335 
ketone levels until they return to normoglycemia and ketones are < 0.6 mmol/l.  336 
 If ketones are <0.6 mmol/l, they will be advised to continue to monitor their glucose until it 337 
returns to normoglycemia and to repeat the ketone measurement in 90 minutes i f necessary  338 
• If correction insulin is administered via insulin syringe, turn Control -IQ off for four hours and until 339 
glucose level has returned to <180 mg/dL.  [ADDRESS_778169] insulin delivery profile settings as needed in accordance with their clinical 343 
practice.  344 
B-24
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from [ADDRESS_778170] a phone (or video -conference) follow -up visit at  3 days, 1 week and 3 weeks, a 346 
clinic follow -up visit at 6 weeks, a phone follow -up visit at 9 weeks, and a final clinic visit at 13 weeks, 347 
within the windows specified below.  348 TARGET 
DAY/WEEK  VISIT OR 
PHONE  TARGET WINDOW  
(AROUND TARGET 
DAY/WEEK)  3 days  P +1 day  1 week  P +2 days  3 weeks  P +7 days  6 weeks  V +7 days  9 weeks  P +7 days  13 weeks  V 91-98 days  If necessary, visits should be completed out -of-window rather than missed. A visit is not considered 349 
missed until the next visit/phone window opens.  350 
The goal will be for all participants to complete all scheduled visits . However, participants who 351 
(because  of unforeseen circumstances or due to changes in contact [CONTACT_66705] 352 
during  the evolving COVID -19 pandemic) are unable or unwilling to return for all follow -up visits 353 
will be permitted to return for key visits only (screening visit, device training  visit) as an alternative to 354 
withdrawal from the study . Remote (phone) visits will s till be performed as scheduled. When a participant [ADDRESS_778171] be obtained prior to conductin g the visit remotely : 359 
• Sponsor approval for the reason the visit cannot be performed in person  360 
• Investigator approval at the site level for the reason the visit cannot be performed in person  361 
In addition, all study procedures listed in section 3.2.1  are to be completed , including upload of the study 362 
device and review of the device data.  If the final visit is performed remotely, participant will mail in the 363 
A1c kit from h ome and mail back the study device s to the study site.  364 
3.2.1  Procedures  at Study Visits  365 
The following procedures will be performed at each visit, unless otherwise specified:  366 
• Review of study device data  367 
• Assessment of compliance with study device use by [CONTACT_66706]  368 
• Assessment of device issues that have occurred  369 
• Assessment of adverse events, using open ended questions to capture hyperglycemic and 370 
hypoglycemic events, and their underlying cause and relationship to the study device or  other parts of 371 
the system (such as the infusion set).  372 
At 13 weeks  (or if at subject withdrawal) , the study  staff will then supervise the participants transition [ADDRESS_778172] of care therapy  as follows:  374 B-25
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  • Study staff will re -evaluate the subject’s baseline therapy doses, noting changes in basal rates, 375 
carbohydrate ratios, and correction factors in use at the end of the trial.  376 
• The study investigator will supervise and confirm the entry of settings in the insulin delivery profile 377 
of the participant ’s home pump at the end of the study.  378 
• Blood draw (venipuncture or fingerstick) for HbA1c measurement at central lab ( Device Training 379 
Visit and 13 weeks only)  [ADDRESS_778173] occur as an 385 
unscheduled visit if these changes are not being performed in window/part of the scheduled study visits 386 
and are not captured as part of a scheduled study v isit. 387 
3.2.3  Exercise and Meal Challenges  388 
Participants will complete 3 meal and 3 exercise challenges during the study . Procedures are described in 389 
section 5.1.  390 
3.3 Early Discontinuation of Study Device  391 
Participants who discontinue the study device prior to 13 weeks,  either by [CONTACT_590486] 392 
decision, will be asked to come for an end of study visit and then will be dropped from the study. 393 
If the visit occurs at 6 weeks or after, blood will be drawn for the central  laboratory  HbA1c measuremen t. 394 
 395 
B-26
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclo sure from 21 CFR 20.61  Chapter 4:  Study Devices and Drugs  396 
4.1 Study Devices  397 
The investigational device (CLC system) includes an insulin pump and a continuous glucose monitor.  398 
4.1.1  Insulin Pump  399 
The study system will include the Tandem t:slim X2 with Control -IQ 1.[ADDRESS_778174] once every 10 days.  403 
4.1.3  Blood Glucose Meter  404 
The study blood glucose meter is the  Contour ® NEXT  (Ascencia Diabetes Care) . 405 
Blood glucose levels will be measured using the study’s blood glucose meter (glucometer) and the 406 
CGM  device will b e calibrated if needed using the study glucometer and strips in accordance with the 407 
manufacturer’s labeling.  408 
4.1.4  Ketone Meter  409 
The study blood ketone meter is the Precision Xtra Blood Glucose and Ketone Monitoring System 410 
(Abbott Diabetes Care) . 411 
Blood ketone lev els will be measured when needed to evaluate prolonged hyperglycemia. The blood 412 
glucose meter component of the Precision Xtra device will not be used.  413 
  414 
4.2 Study Device and Drug Accountability Procedures  415 
Device accountability and inventory will be documented to include detailed inventory records of the study 416 
study CGM supplies, and Tandem insulin pump system.  417 
4.3 Participant Access to Study Device at Study Closure  418 
Participant will return all investigational study devices and supplies (insulin pump, CGM and related 419 
supplies) at study closure. Participant may keep the study ketone meter and study glucometer if these 420 
devices are not marked for investigational use only.  421 
B-27
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  Chapter 5:  Testing Procedures and Questionnaires  [ADDRESS_778175] with study staff after the completion of each challenge .  428 
Hyperglycemia and Hypoglycemia treatment guidelines (sections 3.1.3  and 3.1.2 ) remain in effect for the [ADDRESS_778176] passed since the time of completion of the planned challenge . 434 
5.1.1  Meal Challen ges 435 
The same meal should be used for each of the three meal challenges —either lunch or dinner (participant 436 
choice).  [ADDRESS_778177] of:  438 
• No bolus for the meal  439 
• 50% bolus - calculate the bolus dose using the bolus calculator, and deliver half the 440 
recommended dose of insulin.  441 
• Full bolus for the meal based on calculated bolus dose using the bolus calculator . 442 
 For each meal challenge, participants will:  [ADDRESS_778178] manual insulin bolus 444 
more than two hours prior to the meal .   445 
2. Only begin the meal challenge if CGM  glucose is between 70 mg/dL and 200 mg/dL.  Subjects 446 
with hyperglycemia > 200mg/dL will reschedule their challenge for another time. If < 70  mg/dL, [ADDRESS_778179] 50 grams carbohydrate for the meal. Each participant will use the same meal 449 
for all of their meal challenges in the study. Participants will be encou raged to use the same 450 
frozen entrée of their choice for consistency.  451 
4. Write down the start and end time of eating the meal, as well as the meal content (to include 452 
amount of carbohydrate, protein and fat) on the study provided logbook.  453 
5. Not give an additiona l bolus for up to 3 hours after the meal challenge, unless BG is above 300 454 
mg/dL for more than 1 hour, or symptoms of hyperglycemia  develop.  455 
6. Not take additional carbohydrates for up to 3 hours after the meal challenge, unless BG is < 70 456 
mg/dL, or symptoms of hypoglycemia develop.  457 
7. Not exercise for 3 hours after the meal challenge.  458 
8. After the meal  is completed, perform an SMBG (fingerstick) glucose check 1 hour after, prior to 459 
bed, and once overnight . 460 B-28
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  9. Notify the site within 24 hours after completion of each meal challenge . 461 
10. The meal challenge will end 3 hours after the meal  is completed . 462 
5.1.2  Exercise Challenges  463 
For each exercise challenge, participants will:  [ADDRESS_778180] extra carbohydrate containing snacks and glucagon on hand during and after exercise.  465 
2. Per their usual routine and investigator guidance, c onsider activation of “exercise activity ” on the [ADDRESS_778181] half an hour of moderate activity . Exercise does 471 
not need to be the same activity each time . 472 
5. Only begin exercise if CGM glucose is ≥ 120 mg/dL and CG M glucose is not trending [ADDRESS_778182] insulin dose, type of exercise 475 
performed, as well as the start and stop time of each exercise session in the study logbook  (as this 476 
may not correlate ex actly with exercise activity use on the pump) . Participants may take breaks if 477 
needed , as long as the full hour of activity is completed.  478 
7. Stop the exercise challenges at any point for injury or development of new symptoms ; [ADDRESS_778183] pain/pressure, feeling unwell, development of hypoglycemic symptoms, 480 
undue shortness of breath, signs of poor perfusion (leg pain/claudication), or for any other reason.  481 
8. After the exercise challenge  is completed , perform an SMBG (fing erstick) glucose check 1 hour 482 
after, prior to bed, and once overnight . 483 
9. Notify the site within 24 hours after completion of each exercise challenge . Participants will be 484 
asked  if they develop ed new symptoms and review guidance on the need to stop future exercise 485 
challenges if any adverse events or new symptoms occurred per clinician judgement based on the 486 
severity of symptoms.  487 
10. The exercise challenge will end after 1 hour of the required activity  is completed.  488 
5.2 Laboratory Testing  489 
5.2.1  HbA1c  490 
HbA1c measurement will be performed locally at the Screening visit.  491 
An additional blood sample will be obtained (venipuncture or fingerstick) and sent to  the central 492 
laboratory  at the Control -IQ 1.5 Training visit an d at the 13 -week visit  (or at early withdrawal of the [ADDRESS_778184] 6 weeks of follow -up). 494 
5.2.2  Urine Pregnancy  495 
Urine pregnancy testing performed locally at clinical site for females of child -bearing potential at the 496 
screening visit, at the start of study device use,  and anytime pregnancy is suspected.  497 
B-29
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  Chapter 6:  Unanticipated Problem, Adverse Event, an d 498 
Device Issue Reporting  499 
6.1 Unanticipated Problems  500 
Site investigators will promptly report to the Coordinating Center and Sponsor on an eCRF all 501 
unanticipated problems meeting the criteria below. For this protocol, an unanticipated problem is an 502 
incident, experience, or outcome that meets all of the following criteria:  503 
• Unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are 504 
described in the protocol related documents, such as the IRB -approved research pro tocol and 505 
informed consent document; and (b) the characteristics of the subject population being studied  506 
• Related or possibly related to participation in the research (possibly related means there is a [ADDRESS_778185] been caused by [CONTACT_941] 508 
procedures involved in the research)  509 
• Suggests that the research places participants or others at a greater risk of harm than was previously 510 
known or recognized (including physical, psychological, economic, or social ha rm) [ADDRESS_778186] be reporte d to the study IRB  within seven calendar days of 514 
recognition. The Sponsor will report to the appropriate regulatory authorities if the IRB determines that 515 
the event indeed meets the criteria of an Unanticipated Problem requiring additional reporting.  516 
6.2 Adver se Events  517 
6.2.1  Definitions  518 
Adverse Event (AE) : Any untoward medical occurrence (including laboratory findings) associated with 519 
study procedures, the use of a device, biologic in a study participant, including any comparator used, 520 
irrespective of the relationshi p between the adverse event and the device(s) under investigation (referred 521 
to as Adverse Reaction  when caused by a drug).  522 
Serious Adverse Event (SAE) : Any untoward medical occurrence that meets at least one of the following:  523 
• Results in death.  524 
• Is life -threatening; (a non -life-threatening event which, had it been more severe, might have become 525 
life-threatening, is not necessarily considered a serious adverse event).  526 
• Requires inpatient hospi[INVESTIGATOR_1081].  527 
• Results in pe rsistent or significant disability/incapacity or substantial disruption of the ability [ADDRESS_778187] normal life functions (sight threatening).  529 
• Is a congenital anomaly or birth defect.  530 
• Is considered a significant medical event by [CONTACT_590487] (e.g., may 531 
jeopardize the participant or may require medical/surgical intervention to prevent one of the  outcomes 532 
listed above).  [ADDRESS_778188] (UADE) : Any serious adverse effect on health or safety or any [ADDRESS_778189], problem, or death 535 
was not previously identified in nature, severity, or degree of incidence in the investigational plan or 536 B-30
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  application (including a supplementary plan or applicatio n), or any other unanticipated serious problem 537 
associated with a device that relates to the rights, safety, or welfare of participants (21 CFR 812.3(s)).  [ADDRESS_778190] (ADE) : Any untoward medical occurrence in a study participant which the device [ADDRESS_778191] contributed (Note that an Adverse Event Form is to be 540 
completed in addition to a Device Issue s Form, unless excluded from reporting as defined in section 541 
6.2.2).  542 
Comparator : Medical device, therapy (e.g. active treatment, normal clinical practice), placebo or no 543 
treatment, used in the control group in a clinical investigation. (ISO [ZIP_CODE]:2020)  544 
Device Complaints and Malfunctions : A device complication or complaint is something  that happens 545 
to a device or related to device performance, whereas an adverse event happens to a participant . A device 546 
complaint may occur independently from an AE, or along with an AE . An AE may occur without a 547 
device  complaint or there may be an AE rela ted to a device complaint . A device malfunction is any 548 
failure of a device to meet its performance specifications or otherwise perform as intended . 549 
Performance  specifications include all claims made in the labeling for the device . The intended 550 
performance of a device refers to the intended use for which the device is labeled or marketed. 551 
(21 CFR  803.3) . Note: for reporting purposes, sites will not be asked to distinguish between device 552 
complaints and  malfunctions.  553 
Use Error : User action or lack of user acti on while using the medical device (3.34) that leads to a 554 
different  result than that intended by [CONTACT_3460]. Includes the inability of 555 
the user to complete a task. Use errors can result from a mismatch between the characteristi cs of the user, 556 
user interface, task or use environment. Users might be aware or unaware that a use error has occurred. 557 
An unexpected physiological response of the patient is not by [CONTACT_3461] a use error. A malfunction 558 
of a medical device that caus es an unexpected result is not considered a use error. (ISO [ZIP_CODE]:2020)  559 
6.2.2  Reportable Adverse Events  560 
A reportable adverse event includes all events meeting the definition of an adverse event, except for the 561 
following:  562 
• Hypoglycemia and hyperglycemia not meeting the criteria below will not be recorded as adverse [ADDRESS_778192] or discontinuation of the study device or 564 
study drug.  565 
• Skin reactions from sensor or pump infusion set plac ement are only reportable if severe and/or 566 
required treatment.  567 
B-31
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  All reportable AEs —whether volunteered by [CONTACT_2299], discovered by [CONTACT_66708] [ADDRESS_778193], or other means —will be re ported 569 
on an AE form online . Each AE form is reviewed by [CONTACT_66709] 570 
the coding and the reporting that is required.  571 
6.2.3  Hypoglycemic Events  572 
Hypoglycemia is only reportable as an adverse event when one of the following cri teria is met:  573 
• a hypoglycemic event occurred meeting the following definition of severe hypoglycemia:  the event 574 
required assistance of another person due to altered consciousness, and required another person to 575 
actively administer carbohydrate, glucagon, o r other resuscitative actions . This means that the 576 
participant was impaired cognitively to the point that he/she was unable to treat himself/herself, was 577 
unable to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or experienced 578 
seizure or loss of consciousness . These epi[INVESTIGATOR_66683] 579 
induce seizure or loss of consciousness . If glucose measurements are not available during such an 580 
event, neurological recovery attributable to the restoration  of glucose to normal is considered 581 
sufficient evidence that the event was induced by a  low glucose concentration.  582 
• evaluation or treatment was obtained at a health care provider facility for an acute event involving [ADDRESS_778194] ed the site and received guidance following the occurrence of 584 
an acute event involving hypoglycemia  585 
When a severe hypoglycemia event occurs (as defined above), a n Adverse Event Form  should be [ADDRESS_778195] to 587 
reporting requirements. When a severe hypoglycemia event occurs during use of a study device, it 588 
generally will be considered to be unrelated to the device (per section 6.2.5)  if the device functioned  as 589 
intended and there does not appear to be a flaw in how the device is intended to function.  590 
6.2.4  Hyperglycemic/Ketotic Events  591 
Hyperglycemia is only reportable as an adverse event when one of the following criteria is met:   592 
• the event involved DKA, as defined  by [CONTACT_3467] (DCCT) and 593 
described below  594 
• evaluation or treatment was obtained at a health care provider facility for an acute event involving 595 
hyperglycemia or ketosis, or the participant contact[CONTACT_590488] 596 
manage the hyperglycemia/ketosis  597 
• blood ketone level ≥ 0.6 mmol/L, even if there was no communication with a health care provider at 598 
the time of the event  599 
Hyperglycemic events are classified as DKA if the following are present:  600 
• Symptoms such  as polyuria, polydipsia, nausea, or vomiting;  601 
• Serum ketones >1.5 mmol/L or large/moderate urine ketones;  602 
• Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate (or CO2) <15; and  603 
• Treatment provided in a health care facility  604 
When a hyperglyc emia/ketotic event qualifies as an SAE as defined in section 6.2.[ADDRESS_778196] to reporting requirements. Hyperglycemia events not meeting criteria  for DKA 607 B-32
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  generally will not be considered as serious adverse events unless one of the SAE criteria in section 6.2.1  608 
is met.  609 
DKA can occur at “euglycemic” glucose levels  less than 250 mg/dL , and may occur more commonly  in 610 
indiv iduals takin g adjuvant medications for glucose control such as SGLT -2 inhibitors . This should be 611 
reported as a DKA event if it occurs.  612 
When a hyperglycemia/DKA event occurs during use of a study device, it generally will be considered to 613 
be unrelated to the device (per section 6.2.5 ) if the device functioned as intended and there does not 614 
appear to be a flaw in how the device is intended to function.  615 
6.2.5  Relationship of Adverse Event to Study Investigational Device  616 
The study investigator will assess the relationship of any adverse event to the study device or study drug. 617 
The Medical Monitor also will make this assessment, which may or may not agree with that of the study 618 
investigator. Reporting requirements will be based on the Medical Monitor’s assessmen t. 619 
To ensure consistency of adverse event causality assessments, investigators should apply the following 620 
general guidelines when determining whether an adverse event is related to a study device or study drug:  621 
Unrelated:  The AE is clearly not related to a study drug/device and a likely alternative etiology exists 622 
such as an underlying disease, environmental or toxic factors or other therapy.  623 
Unlikely Related:  The AE does not follow a reasonable temporal sequence during or  after use of study 624 
drug/device and a more likely alternative etiology exists such as an underlying disease, environmental or 625 
toxic factors, or other therapy.  626 
Possibly Related:  The AE occurred in a reasonable time during or after use of study drug/device;  but 627 
could be related to another factor such as an underlying disease, environmental or toxic factors, or other 628 
therapy; and there is a possible, though weak, scientific basis for establishing a causal association 629 
between the AE and the study drug/device.  630 
Probably Related:  The AE occurred in a reasonable time during or after use of study drug/device; is 631 
unlikely to be related to another factor such as an underlying disease, environmental or toxic factors, or 632 
other therapy; and there is a plausible, though n ot strong, scientific basis for establishing a causal 633 
association between the AE and the study drug/device.  634 
Definitely Related:  The AE occurred in a reasonable time during or after use of study drug/device; 635 
cannot be explained by [CONTACT_590489], environmental or toxic factors, or 636 
therapy; and there is a strong scientific basis for establishing a causal association between the AE and the 637 
study drug/device.  638 
Events determined to be Possibly Related , Probably Related , or Definite ly Related  will be considered 639 
‘Related’ with respect to any required IRB and FDA reporting.  640 
6.2.6  Severity (Intensity) of Adverse Events  641 
The severity (intensity) of an adverse event will be rated on a three -point scale: (1) mild, (2) moderate, 642 
or (3) severe . A severity assessment is a clinical determination of the intensity of an event. Thus, a severe 643 
adverse event is not necessarily serious . For example, itching for several days may be rated as severe, but 644 
may not be clinically serious.  645 
MILD: Usually transient, requires no special treatment, and does not interfere with the participant’s daily 646 
activities.  647 
B-33
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  MODERATE: Usually causes a low level of inconvenience, discomfort or concern to the participant 648 
and may interfere with daily activities, but is usually ameliorat ed by [CONTACT_66712] 649 
participant is able to continue in study.  650 
SEVERE: Interrupts a participant’s usual daily activities, causes severe discomfort, may cause 651 
discontinuation of study device, and generally requires systemic drug therapy or other treatment.  652 
6.2.7  Expectedness  653 
For a serious adverse event that is considered possibly related to study device, the Medical Monitor  will 654 
classify the event as unexpected if the nature, severity, or frequency of the event is not consistent with the 655 
risk info rmation previously described in the protocol, labeling, or Investigator Brochure . 656 
6.2.8  Coding of Adverse Events  657 
Adverse events will be coded using  the MedDRA dictionary.  658 
6.2.9  Outcome of Adverse Events  659 
The outcome of each reportable adverse event will be classified by [CONTACT_3470]:  660 
• RECOVERED/RESOLVED – The participant recovered from the AE/SAE without sequelae . Record 661 
the AE/SAE stop date.  662 
• RECOVERED/RESOLVED WITH SEQUELAE – The event persisted and had stabilized without [ADDRESS_778197] the AE/SAE stop date.  664 
• FATAL – A fatal outcome is defined as the SAE that resulted in death . Only the event that was the 665 
cause of death should be reported as fatal . AEs/SAEs that were ongoing at the time of death; 666 
however, were not the cause of death, will be recorded as “resolved” at the time of death.  667 
• NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined as the event 668 
was ongoing with an undetermined outcome.  669 
An ongoing outcome will require follow -up by [CONTACT_66713] 670 
of the AE/SAE. The outcome of an ongoing event at the time of death that was not the cause of 671 
death, will be updated and recorded as “resolved” with the date of death recorded as the stop 672 
date.  673 
• UNKNOWN – An unknown outcome is de fined as an inability to access the participant or the 674 
participant’s records to determine the outcome (for example, a participant that was lost to follow -up). 675 
If any reported adverse events are ongoing when a participant completes the study (or withdraws),  [ADDRESS_778198] of improvement or change, even after the participant has completed all 678 
applicable study visits/contacts. For all other advers e events, data collection will end at the time the 679 
participant completes the study. Note: participants should continue to receive appropriate medical care 680 
for an adverse event after their participation in the study ends.  681 
6.3 Reportable Device Issues  682 
All UADEs and ADEs as defined in section 6.2.1  will be reported as both a ‘device issues ’ and ‘adverse 683 
event ’, except for skin reactions from CGM sensor placement or pump infu sion set placement that do not 684 
require pharmacologic treatment.  685 
B-34
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from [ADDRESS_778199] not been met:  688 
• CGM sensor lasting fewer days than expected per manufacturer  689 
• CGM tape adherence issues  690 
• Pump infusion set insertion lasting fewer days than expected per manufacturer  691 
• Battery lifespan deficiency due to inadequate charg ing or extensive wireless communication  692 
• Intermittent device component disconnections/communication failures not requiring system 693 
replacement or workaround/resolution not specified in user guide/manual.  694 
• Device issues clearly addressed in the user guide manu al that do not require additional [ADDRESS_778200]  be reported 698 
by [CONTACT_66714] 1 working day of the site becoming aware of  the event . This can occur 699 
via phone or email, or by [CONTACT_590490]. If the form (s) are not 700 
initially completed, they should be competed as soon as possible after there is sufficient information to 701 
evaluate the event. All other reportable ADEs and other reportable AEs should be submitted by 702 
completion on the eCRF (s) within  7 days of the site becoming aware of the event.  703 
The Sponsor will notify all participating investigators of any adverse event that is serious,  related, and 704 
unexpected. Notification will be made within 10 working days after the Sponsor  becomes aware of the 705 
event.  706 
Each principal investigator [INVESTIGATOR_590479] -related adverse events and abiding 707 
by [CONTACT_66716]/her Institutional Review Board or Ethics Committee.  708 
Upon receipt of a qualifying event, the Sponsor will investigate the event to determine  if a UADE has 709 
occurred, and if indicated, report the results of the investigation to all overseeing IRBs, and the FDA 710 
within 10 working days of the Sponsor becoming aware of the UADE per 21CFR 812.46(b). The Sponsor [ADDRESS_778201] led to a UADE, including device complaints and malfunction s, irrespective 717 
of whether an adverse event occurred.  718 
6.5 Safety Oversight  719 
The study Sponsor’s Medical Director  will serve as Medical Monitor, and will review all adverse events , 720 
including all cases of severe hypoglycemia and DKA,  and adverse device events tha t are reported during 721 
the study . SAEs typi[INVESTIGATOR_66684] 1 working day  of reporting . Other AEs typi[INVESTIGATOR_590480] 722 
reviewed on a weekly basis , as per the study safety management plan.  723 
The Medical Monitor will determine if the events require ex pedited reporting to FDA, IRB and/or all 724 
participating sites. In addition, the Medical Monitor will confirm the MedDRA code assigned and 725 
adjudicate events for relatedness to the study procedure and investigational device, assess serious ness and 726 
severity, a nd determine if the event the event is anticipated or unanticipated. Both the investigator’s and 727 B-35
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  Medical Monitor’s assessments will be recorded, however, t he adjudication decision of the Medical 728 
Monitor will be used for the final classification of events, including relatedness to the study procedures 729 
and/or the investigational device, for the determination of safety endpoints and for all regulatory reports, [ADDRESS_778202] labeling, and publications or presentations.   731 
6.6 Stoppi[INVESTIGATOR_2121]  732 
6.6.1  Participant Discontinuation of Study Device  733 
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or DKA event 734 
(or a malfunction that could have led to severe hypoglycemia or DKA), use of the study device will be 735 
suspended for that part icipant while the problem is diagnosed. The UADE will be reported to the IRB and 736 
FDA. After assessment of the problem and any correction, use of the study device will not be restarted 737 
until approval is received from the IRB and FDA.  738 
In the absence of a dev ice malfunction, use of the study device by a participant will be discontinued if 739 
any of the following occur:  740 
• The investigator believes it is unsafe for the participant to continue on the intervention . This could be 741 
due to the development of a new medical  condition or worsening of an existing condition; or 742 
participant behavior contrary to the indications for use of the device that imposes on  the participant’s 743 
safety  744 
• The participant requests that the treatment be stopped  745 
• Participant pregnancy  746 
• Two distinct e pi[INVESTIGATOR_590481] 6.2.4  747 
• Two distinct severe hypoglycemia events as defined in section 6.2.3  748 
• One epi[INVESTIGATOR_590482] 6.2.[ADDRESS_778203] to 751 
determination of cause and whether the occurrence of the event can be attributed to use of t he study 752 
device or study drug.   753 
An additional requirement for continued study device use following a single DKA or severe 754 
hypoglycemia event will be that the site investigator believes that the event is unlikely to recur and that 755 
it is safe for the partici pant to continue to use the system. Additionally, if the Medical Monitor determines 756 
that the occurrence of the event indicates that it is not safe for the participant to continue to use the study 757 
device, use will be discontinued.  758 
6.6.2  Criteria for Suspending or  Stoppi[INVESTIGATOR_3396]  759 
In addition to the suspension of device use due to a UADE as described in section 6.6.1 , study activities 760 
could be similarly suspended if the manufacturer of any constituent study device requires stoppage of 761 
device use for safety re asons (e.g. product recall) . The affected study activities may resume if the 762 
underlying problem can be corrected by a protocol or system modification that will not invalidate the 763 
results obtained prior to suspension.  764 
Closed -loop system use will also be suspended if there are three or more cases of severe hypoglycemia or 765 
three or more cases of hyperglycemia/ketotic events qualifying as SAEs across the entire study in [ADDRESS_778204] initiated Control -IQ technology use . The IRBs and FDA will be notif ied. After 767 
assessment of the problem and any corrections are implemented, use of the closed -loop system may be 768 
restarted if approval is received from the IRBs and FDA.  769 B-36
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61   770 
 771 
B-37
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  Chapter 7:  Miscellaneous Considerations  772 
7.1 Drugs Used as Part of the Protocol  773 
Subjects may use their own Humalog (insulin lispro) or Novolog (insulin aspart)  during the Treatment [ADDRESS_778205] as part of the study . 775 
7.2 Collection of Medical Conditions and Medications  776 
Pre-Existing Conditions : Any medical condition that is either present at screening, a chronic disease, [ADDRESS_778206] the participant’s health  during the course of the study (e.g., prior 778 
myocardial infarction or stroke) will be recorded.  779 
Medical Conditions Developi[INVESTIGATOR_66686] : Medical conditions developi[INVESTIGATOR_66687] 780 
be reviewed by [CONTACT_198672] r their relationship to the study device . 781 
Medications : All medications in use at the time of screening or added during the course of the study will 782 
be recorded . Nutraceuticals and preventative treatment also will be recorded . Medications only taken as 783 
needed either can be recorde d when prescribed or only recorded if used during the study . Glucagon for 784 
treatment of severe hypoglycemia will only be recorded if used during the study.  785 
7.3 Prohibited Medications, Devices, Treatments, and Procedures  786 
Treatment with any insulin other than Hum alog or Novolog insulin is not permitted with the study device.  787 
Treatment with sulfonylureas, meglitinides or Symlin is not permitted.  788 
No new additional non-insulin glucose lowering medications may be added during the trial.  789 
Participants taking GLP -1 rece ptor agonists, DPP -4 inhibitors, and/or SGLT -[ADDRESS_778207] 3 month s. No new medications for weight loss may be added during the  trial.  795 
Additional medications may be excluded per judgement of the investigator.  796 
The investigational study devices (t:slim X2 insulin pump, Dexcom CGM sensor) must be removed 797 
before magnetic r esonance imaging (MRI), computed tomography (CT) or diathermy treatment. [ADDRESS_778208] a glucagon preparation for rescue therapy for severe 801 
hypoglycemia.  802 
7.5 Pregnancy Reporting  803 
If pregnancy occurs, the participant will be discontinued from the study . The occurrence of pregnancy 804 
will be reported to the Coordinating Center within seve n days and to the IRB as an Unanticipated 805 
Problem within seven calendar days.  806 B-38
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  7.6 Participant Compensation  807 
Participant compensation will be specified in the informed consent form.  808 
7.7 Participant Withdrawal  809 
Participation in the study is voluntary, and a participant may withdraw at any time . For participants who 810 
withdraw, their data will be used up until the time of withdrawal.  811 
 812 
B-39
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  Chapter 8:  Statistical Considerations  [ADDRESS_778209] completing approximately 3 months use of the study system  with the removal of 819 
the basal clippi[INVESTIGATOR_383856], and not  for assessing safety endpoints and is not based on statistical principles.  820 
8.3 Outcome Measures  821 
Primary  Safety Endpoints  822 
• Rate of s evere hypoglycemia as defined in section 6.2.3  823 
• Rate of diabetic ketoacidosis as defined in section 6.2.4  824 
• Number of u nanticipated adverse device effects  825 
• Number of other serious adverse events  826 
Secondary Safety Endpoints  827 
• All reportable adverse events  828 
• CGM hypoglycemia outcomes  829 
 Overall % time <54 mg/dL  830 
 Overall % time <70 mg/dL  831 
Exploratory Endpoints  832 
• Times in ranges -overall (70 -180 mg/dL, >180 mg/dL, >25 0 mg/dL, 70 -140 mg/dL)  833 
• Mean glucose  834 
• Overall variability (CV and SD)  835 
• HbA1c change from baseline  836 
• CGM metrics for hypoglycemia, hyperglycemia, and variability during daytime and nighttime  837 
8.4 Analysis Datasets  838 
Safety analysis set: All participants who initiate t he Treatment Period and use the study device  839 
CGM analysis set: Any member of the Safety Analysis Set who has at least 24 hours of CGM data during 840 
the Treatment Period. CGM data occurring within the meal and exercise challenge windows will not be 841 
included i n this set.  842 
Meal and exercise challenge set: Any member of the Safety Analysis Set who has at least 24 hours of 843 
CGM data during the Treatment Period. Only CGM data occurring within the meal and exercise challenge 844 
windows will be included in this set.  845 
B-40
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  8.5 Stati stical Methods  846 
8.5.1  Analysis of the Safety Event Endpoints  847 
Safety events (ie, not including CGM defined events) will be tabulated for each type of event as the 848 
number of events per participant, the number of participants with > 1 event, and the rate of events p er 849 
100 person -years.  850 
Since study eligibility excluded participants with 2 or more severe hypoglycemia or DKA events in the 851 
prior 6 months, an unbiased comparison of the event rate during the Treatment Period with the pre -study 852 
event rate is not possible . Therefore, the severe hypoglycemia and DKA event rates will be compared 853 
with the T1D Exchange data,4 which reported the frequency of 1 or more severe hypoglycemia and DKA 854 
events in the prior 3 months . The proportion of participants with events during the Tr eatment Period will 855 
be compared with the T1D Exchange frequency.  856 
8.5.2  Analysis of CGM Endpoints  857 
CGM metrics will be computed for the Treatment Period. CGM metrics will be computed over 24 hours, 858 
during daytime (6am -11:59pm), and  during nighttime ( 12am -5:59am).  859 
The main statistical comparison will be made between the Treatment Period and historical data . 860 
8.5.3  Intervention Adherence  861 
The following tabulations will be performed:  862 
• Sensor use –percent time of use  as a function of overall treatment period  863 
• Closed loop system u se–percent time of use  as a function of overall treatment period  864 
• % time in different operational modes  as a function of overall treatment period  865 
8.6 Protocol Adherence and Retention  866 
The following tabulations and analyses will be performed to assess protocol ad herence for the study:  867 
• Number of protocol deviations  868 
• Flow chart accounting for all enrolled participants  869 
• Number of and reasons for unscheduled visits and phone calls  870 
• Number of participants who were enrolled but did not enter the Treatment Period and reas ons 871 
• Number of participants who stopped treatment and reasons  872 
8.7 Baseline Descriptive Statistics  873 
Baseline demographic and clinical characteristics of the cohort of participants who initiate the Treatment 874 
Period will be summarized in a table using summary stati stics appropriate to the distribution of each 875 
variable. Descriptive statistics will be displayed by [CONTACT_66723]:  876 
• Age 877 
• Sex 878 
• Race/Ethnicity  879 
• Socio -economic factors (income, education, and/or insurance status)  880 B-41
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  • Diabetes duration  881 
• HbA1c  882 
• BMI  883 
• Total daily insulin  884 
• Prior severe hypoglycemia and DKA events  885 
8.8 Additional Tabulations and Analyses  886 
The following data will be tabulated at baseline and at or over 13 weeks  887 
• Insulin metrics (units/kg): total daily insulin, total daily basal insulin, total daily bolus insulin (plus 888 
total daily manual bolus, total daily automated bolus)  [ADDRESS_778210] to device issues:  891 
• Reported device issues according to type of issue  892 
8.10 Planned Interim Analyses  893 
No formal i nterim analyses are planned . 894 
8.11 Subgroup Analyses  895 
Results will be tabulated according to baseline HbA1c  and total daily insulin . 896 
8.12 Multiple Comparison/Multiplicity  897 
Safety event endpoints will not be corrected for multiple comparisons.  898 
8.13 Analysis of Meal and Exer cise Challenges  899 
The meal and exercise challenges will be analyzed with the same CGM metrics and safety outcomes 900 
above to be tabulated during  and after (specifically to include the time period through 3 hours after each 901 
meal challenge [end of meal challenge] and through 2 hours  after the completion of each exercise 902 
challenge) and overnight (12am -5:59am) after each challenge  performed . Separate analysis will be 903 
conducted for each type of challenge . These challenge analysis period s will be excluded from the analysis 904 
of main CGM metrics. 905 
B-42
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  Chapter 9:  Data Collection and Monitoring  906 
9.1 Case Report Forms and Other Data Collection  907 
The main study data are collected on electronic case report forms (eCRFs). When data are directly 908 
collected in electronic case report forms, this will be considered the source data . For any data points 909 
for which the eCRF is not considered source (e.g. lab results that ar e transcribed from a printed report [ADDRESS_778211], study specific source worksheets, etc. ), the 911 
original source documentation will be maintained in the participant’s study chart or  medical record . This [ADDRESS_778212] . These documents should be retained for a longer period, however, 925 
if required by [CONTACT_427] . No records will be destroyed without the written consent of the sponsor, 926 
if applicable. It is the responsibility of the sponsor to inform the investigator when these documents no 927 
longer need to be r etained.  928 
9.3 Quality Assurance and Monitoring  929 
Designated personnel from the Coordinating Center will be responsible for maintaining quality 930 
assurance  (QA) and QC systems to ensure that the clinical portion of the trial is conducted and data  are [ADDRESS_778213] 936 
and monitoring will conform with  21 Code of Federal Regulations (CFR) 812. This plan will descri be in [ADDRESS_778214] importance for monitoring at the site are participant eligibility and adverse events . 940 
Therefore, the monitoring plan will focus on these areas . As much as possible, remote monitoring will be 941 
performed in real -time with on -site monitoring performed to evaluate the verity and completeness of 942 
the key site data . Elements of the monitoring plan  may include:  943 
B-43
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  • Qualification assessment, training, and certification for sites and site personnel  944 
• Oversight of Institutional Review Board (IRB) coverage and informed consent procedures  945 
• Central (remote) data monitor ing: validation of data entry, data edits/audit trail, protocol review of 946 
entered data and edits, statistical monitoring, study closeout  947 
• On-site monitoring (site visits): source data verification, site visit report  948 
• Agent/Device accountability  949 
• Communication s with site staff  950 
• Patient retention and visit completion  951 
• Quality control reports  952 
• Management of noncompliance  953 
• Documenting monitoring activities  954 
• Adverse event reporting and monitoring  [ADDRESS_778215] access to all trial related source data/documents, and reports 959 
for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_66724] 960 
authorities.  961 
9.4 Protocol Deviations  962 
A protocol deviation is any noncompliance wit h the clinical trial protocol, GCP, or procedure 963 
requirements . The noncompliance may be either on the part of the participant, the investigator, or the 964 
study site staff . A significant (or major) deviation is any deviation that departs from the established [ADDRESS_778216] ive and preventive action plan shall be developed by [CONTACT_779] 968 
and implemented promptly.  969 
The site PI/study staff is responsible for knowing and adhering to their IRB requirements . Further details 970 
about the handling of protocol deviations will be included in  the monitoring plan.  971 
 972 
B-44
 
Confidential  
Contains  trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  Chapter 10:  Ethics/Protection of Human Participants  [ADDRESS_778217]  974 
The investigator will ensure that this study is con ducted in full conformity with Regulations for the 975 
Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR 976 
Part 56, and/or the ICH E6.  977 
10.2 Institutional Review Boards  978 
The protocol, informed consent form(s), recruitment m aterials, and all participant materials will be [ADDRESS_778218] 980 
be obtained before any participant is enrolled . Any amendment to the protocol will require review and 981 
approval by [CONTACT_3484]. All changes to the consent form 982 
will be IRB approved; a determination will be made regarding whether previously consented participants 983 
need to be re -consented.  984 
10.3 Informed Consent Process  985 
10.3.1  Consent Procedures and Documentation  986 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study 987 
and continues throughout the individual’s study participation . Extensive discussion of risks and possible [ADDRESS_778219] by [CONTACT_3486], their staff, and the 1003  
sponsor(s) and their agents . This confidentiality is extended to cover testing of biological samples and [ADDRESS_778220] all documents a nd records required to be 1010  
maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) 1011  
and pharmacy records for the participants in this study . The clinical study site will permit access to such 1012  
records.  1013  B-45
 
Confidential  
Contains  trade secrets and/or confidential information exempt from disclosure from 21 CFR 20.61  The s tudy participant’s contact [CONTACT_66725] 1014  
during the study . At the end of the study, all records will continue to be kept in a secure location for as 1015  
long a period as dictated by [CONTACT_3488] , institutional policies, sponsor requirements  and applicable 1016  
regulations . 1017  
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will 1018  
be transmitted to and stored at the Coordinating Center . This will not include the participant’s contact [INVESTIGATOR_1660] [ADDRESS_778221] protected . At the end of the study, all study databases will be de - 1023  
identified and archived at the Coordinating Center.  1024  
10.3.3  Future Use  of Stored Specimens and Data  1025  
Data collected for this study will be analyzed and stored at the Coordinating Center . After the study is 1026  
completed, a dataset will be provided to the study Sponsor.  1027  
No biologic specimens will be stored.  1028  
 1029  
B-46
 
Confidential  
Contains trade secrets and/or confidential information exempt from disclosure from 2 1 CFR 20.61  Chapter 11:  References  [ADDRESS_778222], Anderson SM, Church MM, 1033  
Dadlani V, Ekhlaspour L, Forlenza GP, Isganaitis E, Lam DW, Kollman C, Beck RW; iDCL 1034  
Trial Research Group.  Six -month randomized, multicenter trial of closed -loop control in 1035  
type 1 diabetes. N Engl J Med. 2019; 381:[ADDRESS_778223] E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman  CC, Dokken BB, 1038  
Weinzimer SA, DeBoer MD, Buckingham BA, Cherñavvsky D, Wadwa RP; iDCL Trial 1039  
Research Group. A randomi zed trial of closed -loop control in children with type 1 diabetes. 1040  
N Engl J Med. 2020;  383:836 -845. 1041  
3. Breton M, Kovatchev B. One year real -world use of the Control -IQ advanced hybrid closed 1042  
loop technology. Diabetes Technol Ther . 2021;23:601 -608. 1043  
4. Foster et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 1044  
2016 -2018. Diabetes Technol Ther . 2019; 21:66 -72. 1045  
 1046  
B-47